Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine Atlanta, GA, USA.
Front Oncol. 2012 Dec 17;2:191. doi: 10.3389/fonc.2012.00191. eCollection 2012.
Chemotherapy and radiation therapy (RT) are standard therapeutic modalities for patients with cancers, and could induce various tumor cell death modalities, releasing tumor-derived antigens as well as danger signals that could either be captured for triggering anti-tumor immune response. Historic studies examining tissue and cellular responses to RT have predominantly focused on damage caused to proliferating malignant cells leading to their death. However, there is increasing evidence that RT also leads to significant alterations in the tumor microenvironment, particularly with respect to effects on immune cells and infiltrating tumors. This review will focus on immunologic consequences of RT and discuss the therapeutic reprogramming of immune responses in tumors and how it regulates efficacy and durability to RT.
化疗和放疗(RT)是癌症患者的标准治疗方式,可诱导多种肿瘤细胞死亡方式,释放肿瘤来源的抗原和危险信号,从而触发抗肿瘤免疫反应。历史上研究 RT 对组织和细胞反应的研究主要集中在增殖的恶性细胞受到的损伤导致其死亡上。然而,越来越多的证据表明 RT 还会导致肿瘤微环境发生显著变化,特别是对免疫细胞和浸润肿瘤的影响。这篇综述将重点讨论 RT 的免疫学后果,并讨论如何对肿瘤免疫反应进行治疗性重编程以及它如何调节 RT 的疗效和持久性。